Pfizer acquires BioRexis in move to boost diabetes, protein drug pipeline

Share this article:
Pfizer said today it has acquired BioRexis Pharmaceutical Corporation, a privately-held biopharmaceutical firm working on several diabetes treatments and a novel technology platform for new protein drug candidates. Financial terms of the deal were not disclosed. The technology being used to develop the experimental treatments relies on protein engineering and may have the potential to improve drug tolerability, reduce dosing frequency and improve patient compliance, Pfizer said.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.